Trials / Not Yet Recruiting
Not Yet RecruitingNCT06166472
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The Anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is A Phase I Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of The anti-CLDN18.2 and CD47 Bispecific Antibody AK132 in Advanced Malignant Solid Tumor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK132 | IV infusion, specified dose on specified days. |
Timeline
- Start date
- 2023-12-12
- Primary completion
- 2026-04-24
- Completion
- 2026-07-24
- First posted
- 2023-12-12
- Last updated
- 2023-12-12
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06166472. Inclusion in this directory is not an endorsement.